• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
158010 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
4 {) U/ f0 _; I/ A7 C  e
+ j, M* O. J) G3 h0 K, A5 V; e
/ v7 D, n' E, E$ {Sub-category:0 h% y6 n: W# ~6 Z7 \# B
Molecular Targets & I- }# S4 c" u6 L: k, a( P

$ m1 S1 d5 q; Z2 u
1 ~& q9 M1 X) ^Category:
: y# {1 i& A0 j& i- G% r& f; zTumor Biology
4 ^& R3 g/ W# h3 i4 \- @7 T3 m7 B* U, S: j7 y0 \
, {. Q3 e6 l% t. i# ~
Meeting:
, `/ @" r8 E/ N/ ]. o$ n2011 ASCO Annual Meeting
. K1 h( x" a  d' Z" P8 Y
# `3 d& Q" e2 l) w3 f) K9 H* [; S7 n+ g2 {+ ]) z* d  p
Session Type and Session Title:& R8 x+ u; R* g( G( n9 ~1 y
Poster Discussion Session, Tumor Biology
2 y, R  f% |+ N* l7 g# z$ ^4 b# t$ E" W

# q. q. Z) D' Z; p9 Q, ]" _  lAbstract No:
; {4 {$ b/ n2 }/ ~10517 $ W6 n( _0 l* K  ~; g0 U$ k
" g1 F" q; O: I8 n0 x9 H

: L$ f$ c3 N4 e) j  SCitation:" H% f3 m* D& C7 \  D( X
J Clin Oncol 29: 2011 (suppl; abstr 10517)
" l6 s4 `$ {* q0 d/ t5 L" T
5 o% m* i; k/ m, n. E* l3 o7 T1 v% |
Author(s):
! ]3 S, Q7 U- B! ?, @. ~) D6 ]J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
9 D% j" C7 G9 u% p2 ?# t* F7 \7 Z) M) r9 \

. |1 W, l. t) |2 s+ q0 R9 T
, ^6 a8 M3 B# r! R( j4 L/ L( lAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 ~" u  }; {, s$ }# B- v4 e6 N5 P; }
Abstract Disclosures: Q2 I9 S1 w; s, N
- c4 Q, U& j8 `2 W. \) g3 F" l
Abstract:
4 [9 ?; }  O% b# C9 B
0 S; U" r$ r; `
- @6 a. q; z! M  |Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# W7 ]; j* r" X  B

3 K# a9 X7 j$ O- S8 R
5 ^) t4 ]7 R/ H9 D1 n9 f# C
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
. t, _+ ~+ n$ \1 E没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

) J5 B) X+ [, J2 ~, x6 X/ d& ]' n化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
, t0 o! Q3 \9 z+ q: z" @; ?1 c3 u8 k易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
" ~) e+ j& J, E$ m  k8 @( pALK一个指标医院要900多 ...
! _: V5 S4 S, H- j1 z/ L" d
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?% M+ K* \; g/ N8 V3 |! O

& p* r) ^1 ]: `5 k/ v现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表